Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: LDL Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study

NCT00535886
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Dyslipidemia
Interventions
Man-made Trans FA, Natural Trans FA, Oleic Acid
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Nov 7, 2026, 8:05 AM EST
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 7, 2026, 8:05 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

NCT04781322
View directory record Official record
Conditions
Alcohol Associated Liver Disease, Heavy Drinking Behavior
Interventions
Alirocumab, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

NCT00115024
View directory record Official record
Conditions
Atherosclerosis, Postmenopause
Interventions
Micronized 17B-estradiol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
46 Years to 80 Years · Female only
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 1998
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)

NCT03121209
View directory record Official record
Conditions
Internal Carotid Artery Stenosis, Cognitive Impairment
Interventions
Revascularization, Intensive Medical Management (IMM) alone
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 86 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Nov 7, 2026, 8:05 AM EST
Completed No phase listed Observational

Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant

NCT00510315
View directory record Official record
Conditions
Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
Questionnaires, Laboratory tests, Abdominal MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Nov 7, 2026, 8:05 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

NCT05733325
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Nov 7, 2026, 8:05 AM EST
Completed Not applicable Interventional

Habit Formation for Adherence to Statin Use and LDL Reduction

NCT01798784
View directory record Official record
Conditions
Medication Adherence
Interventions
Sweepstake Incentive 1, Sweepstake Incentive 2, Sweepstake Incentive 3
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Nov 7, 2026, 8:05 AM EST
Active, not recruiting No phase listed Observational

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions
Blood draw, Urine sample collection, DXA scan
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

NCT00999141
View directory record Official record
Conditions
Face-lift, Facial Rhytidectomy
Interventions
FS VH S/D 4 s-apr
Biological
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Beverly Hills, California • Atlanta, Georgia • Evans, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Nov 7, 2026, 8:05 AM EST
Completed No phase listed Observational

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

NCT07023445
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37,688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 7, 2026, 8:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Protein and Insulin Sensitivity Study

NCT00508937
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Metabolic Syndrome, Cardiovascular Disease, Dyslipidemia
Interventions
Diet
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Nov 7, 2026, 8:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Lipoprotein Effects of Substituting Beef Protein for Carbohydrate

NCT00852267
View directory record Official record
Conditions
Healthy, Cardiovascular Disease, Atherogenic Dyslipidemia
Interventions
High Carbohydrate, High Saturated Fat Diet, Low Carbohydrate, High Saturated Fat Diet, Low Carbohydrate, Low Saturated Fat Diet
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional Results available

FS VH S/D 500 S-apr in Vascular Surgery

NCT00892957
View directory record Official record
Conditions
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads
Biological · Other
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Not listed
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Nov 7, 2026, 8:05 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Quercetin on Metabolic Health

NCT05297032
View directory record Official record
Conditions
Quercetin, Lipid Metabolism, Aging
Interventions
Quercetin Phytosome
Dietary Supplement
Lead sponsor
Thorne HealthTech, Inc
Industry
Eligibility
20 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

NCT04964557
View directory record Official record
Conditions
Hyperlipidaemia
Interventions
AZD8233, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Huntsville, Alabama • Canoga Park, California • Lincoln, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 7, 2026, 8:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Resistant Starch Insulin Sensitivity Trial

NCT01027325
View directory record Official record
Conditions
Healthy, Cardiovascular Disease, Atherogenic Dyslipidemia, Insulin Resistance
Interventions
Dietary Intervention
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
20 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Berkeley, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

NCT04652726
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 7, 2026, 8:05 AM EST
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 7, 2026, 8:05 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis

NCT01105715
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Nov 7, 2026, 8:05 AM EST